215 related articles for article (PubMed ID: 28447163)
1. Successful treatment with bendamustine and rituximab for paraneoplastic pemphigus.
Kikuchi T; Mori T; Shimizu T; Koda Y; Abe R; Kurihara Y; Funakoshi T; Yamagami J; Sato H; Tsunoda K; Amagai M; Okamoto S
Ann Hematol; 2017 Jul; 96(7):1221-1222. PubMed ID: 28447163
[No Abstract] [Full Text] [Related]
2. Paraneoplastic pemphigus in a patient with non-Hodgkin's lymphoma.
Plumb R; Doolittle GC
Am J Hematol; 1996 May; 52(1):58-9. PubMed ID: 8638613
[TBL] [Abstract][Full Text] [Related]
3. A skin rash and what lies beneath: paraneoplastic pemphigus, an atypical presentation of follicular cell lymphoma.
Moustafa MA; Seningen JL; Jouni H; Singh PP; el-Azhary RA; Witzig TE
Am J Hematol; 2013 Sep; 88(9):822-3. PubMed ID: 23658142
[No Abstract] [Full Text] [Related]
4. Anti-desmoglein antibody-negative paraneoplastic pemphigus successfully treated with rituximab.
Kanwar AJ; Vinay K; Varma S; Koga H; Ishii N; Hashimoto T
Int J Dermatol; 2015; 54(5):576-9. PubMed ID: 24738571
[No Abstract] [Full Text] [Related]
5. Case of paraneoplastic pemphigus with follicular lymphoma treated with rituximab.
Aoi J; Makino K; Sakai K; Masuguchi S; Fukushima S; Jinnin M; Inoue Y; Koga H; Hashimoto T; Ihn H
J Dermatol; 2013 Apr; 40(4):285-6. PubMed ID: 23398274
[No Abstract] [Full Text] [Related]
6. Paraneoplastic pemphigus occurring after bendamustine and rituximab therapy for relapsed follicular lymphoma.
Higo T; Miyagaki T; Nakamura F; Shinohara A; Asano H; Abe H; Senda N; Yoshizaki A; Fukayama M; Kurokawa M
Ann Hematol; 2015 Apr; 94(4):683-5. PubMed ID: 25199505
[No Abstract] [Full Text] [Related]
7. Paraneoplastic pemphigus associated with fatal bronchiolitis obliterans and intractable mucosal erosions: Treatment with cyclosporin in addition to steroid, rituximab and intravenous immunoglobulin.
Namba C; Tohyama M; Hanakawa Y; Murakami M; Shirakata Y; Matsumoto T; Suemori K; Ishii N; Hashimoto T; Sayama K
J Dermatol; 2016 Apr; 43(4):419-22. PubMed ID: 26506947
[TBL] [Abstract][Full Text] [Related]
8. A case of paraneoplastic pemphigus associated with follicular lymphoma positive only for anti-desmoglein 3 antibody.
Matsuo M; Niwa H; Koga H; Ishii N; Nakamura N; Iwata H
J Dermatol; 2024 May; 51(5):e164-e165. PubMed ID: 38111329
[No Abstract] [Full Text] [Related]
9. Successful treatment of paraneoplastic pemphigus in follicular NHL with rituximab: report of a case and review of treatment for paraneoplastic pemphigus in NHL and CLL.
Heizmann M; Itin P; Wernli M; Borradori L; Bargetzi MJ
Am J Hematol; 2001 Feb; 66(2):142-4. PubMed ID: 11421295
[TBL] [Abstract][Full Text] [Related]
10. Recalcitrant paraneoplastic pemphigus associated with follicular dendritic cell sarcoma: response to prolonged rituximab and ciclosporin therapy.
Hwang YY; Chan JC; Trendell-Smith NJ; Kwong YL
Intern Med J; 2014 Nov; 44(11):1145-6. PubMed ID: 25367731
[No Abstract] [Full Text] [Related]
11. Paraneoplastic pemphigus occurs most commonly in indolent B cell lymphoma.
Morikawa K; Tsuji T; Yamasaki H; Egashira S; Kaguchi A; Kido M; Tsuda H
Acta Haematol; 2014; 132(1):73-4. PubMed ID: 24481059
[No Abstract] [Full Text] [Related]
12. Paraneoplastic pemphigus associated with CD20-positive follicular non-Hodgkin's lymphoma treated with rituximab: a third case resistant to rituximab therapy.
Hoque SR; Black MM; Cliff S
Clin Exp Dermatol; 2007 Mar; 32(2):172-5. PubMed ID: 17342796
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of paraneoplastic pemphigus and bronchiolitis obliterans associated with follicular lymphoma with obinutuzumab and bendamustine.
Kuriyama K; Kitamura Y; Tsuji T; Nishikawa R; Nagata H; Ohshiro M; Sugitani M; Hirakawa Y; Matsumoto Y; Iwai T; Uchiyama H
Curr Probl Cancer; 2022 Apr; 46(2):100813. PubMed ID: 34844771
[TBL] [Abstract][Full Text] [Related]
14. Bendamustine-rituximab in mantle cell lymphoma.
Lipsky A; Martin P
Lancet Haematol; 2017 Jan; 4(1):e2-e3. PubMed ID: 27927585
[No Abstract] [Full Text] [Related]
15. Diagnosis and treatment of follicular lymphoma: an update.
Bargetzi M; Baumann R; Cogliatti S; Dietrich PY; Duchosal M; Goede J; Hitz F; Konermann C; Lohri A; Mey U; Novak U; Papachristofilou A; Stenner F; Taverna C; Zander T; Renner C
Swiss Med Wkly; 2018; 148():w14635. PubMed ID: 30044476
[TBL] [Abstract][Full Text] [Related]
16. Progressive multifocal leukoencephalopathy in patients with follicular lymphoma treated with bendamustine plus rituximab followed by rituximab maintenance.
D'Alò F; Malafronte R; Piludu F; Bellesi S; Cuccaro A; Maiolo E; Modoni A; Leccisotti L; Macis G; Mores N; De Stefano V; Hohaus S
Br J Haematol; 2020 May; 189(4):e140-e144. PubMed ID: 32150646
[No Abstract] [Full Text] [Related]
17. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
[TBL] [Abstract][Full Text] [Related]
18. Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab.
Franceschini E; Pellegrino M; Todisco V; Dolci G; Bettelli F; Meschiari M; Bedini A; Fregni-Serpini G; Grottola A; Guaraldi G; Pecorari M; Sarti M; Luppi M; Perno CF; Mussini C
Infection; 2023 Oct; 51(5):1577-1581. PubMed ID: 37076752
[TBL] [Abstract][Full Text] [Related]
19. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus.
Borradori L; Lombardi T; Samson J; Girardet C; Saurat JH; Hügli A
Arch Dermatol; 2001 Mar; 137(3):269-72. PubMed ID: 11255323
[No Abstract] [Full Text] [Related]
20. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity.
Cheah CY; Nastoupil LJ; McLaughlin P; Fanale MA; Neelapu SS; Fayad LE; Hagemeister FB; Fowler NH
Br J Haematol; 2016 Nov; 175(3):531-533. PubMed ID: 26683805
[No Abstract] [Full Text] [Related]
[Next] [New Search]
